1. >
  2. Investors
  3. >
  4. Regulated Information
  5. >
  6. Press Releases – Reg...


Found 307 Results
Page 4 of 31

Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update

Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]


Onxeo announces the success of its Rights Issue with €9.7 million raised

This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]


Onxeo to Present New Preclinical Data at AACR 2021

Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]

Tags: ,


B-Smart – Interview of Judith Greciet, CEO of Onxeo

Watch the interview (in French)


Onxeo will publish its annual results on April 21, 2021

The Annual General Meeting will be held on June 10, 2021 Paris (France), March 24, 2021 – 6 pm CET […]



Onxeo Launches a Rights Issue to accelerate its R&D programs

This transaction will secure the financing of the strategy and the resources necessary to achieve key clinical milestones until at […]


Onxeo publishes Letter to Shareholders and provides update on its developments

Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]


Onxeo Obtains Non-Dilutive Financing of 5 Million Euros in the Form of State Guaranteed Loans

This financing extends the Company’s cash horizon to the 3rd quarter of 2022   Paris (France), January 28, 2021 – […]


Onxeo to Attend Key Investor and Scientific Conferences

Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]


Page 4 of 31